Nanocarrier-Mediated Immunotherapy for Gynecological Malignancies: Mechanisms, Clinical Translation, and Emerging Nucleic Acid-Based Strategies.
- 1Department of Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China.
- 2Department of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China.
Abstract
Gynecological cancers, including ovarian, cervical, and endometrial cancers, remain major contributors to female morbidity and mortality worldwide. Conventional treatments-surgery, chemotherapy, and radiotherapy-have improved outcomes, but advanced or recurrent disease is still associated with poor prognosis, chemoresistance, and tumor heterogeneity. Immunotherapy has emerged as a transformative strategy because of its specificity and potential for durable responses. However, the immunosuppressive tumor microenvironment and inefficient delivery of immunotherapeutic agents limit clinical benefit. Nanocarriers, including organic, inorganic, and biomimetic platforms, can improve targeted delivery, sustained release, biocompatibility, and tumor microenvironment remodeling, thereby enhancing immunotherapy. This review summarizes major immunotherapeutic modalities for gynecological cancers-immune checkpoint blockade, CAR-T cell therapy, tumor vaccines, and oncolytic viruses-and the classification and characteristics of commonly used nanocarriers. We focus on nanocarrier-mediated immunotherapeutic mechanisms in ovarian, cervical, and endometrial cancers, and further highlight emerging lipid nanoparticle/mRNA and programmable RNA delivery strategies. Finally, we analyze challenges in clinical translation and provide perspectives for future development, aiming to support fundamental research and clinical application of nano-immunotherapy in gynecological malignancies.
Related
- Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies
- Nanomaterial-based therapeutic strategies for systemic autoimmune rheumatic diseases: from molecular mechanisms to preclinical translation
- Cross-and-Capture: A Dual-Ligand PAMAM Nanocarrier for Sequential BBB Penetration and Ischemic Lesion Retention of Breviscapine
- Bone-targeted nanocarrier systems in osteoporotic therapy: design strategies and therapeutic potential
BibTeX
@article{fu2026nanocarriermediated,
title = {{Nanocarrier-Mediated Immunotherapy for Gynecological Malignancies: Mechanisms, Clinical Translation, and Emerging Nucleic Acid-Based Strategies.}},
author = {Miaomiao Fu and Ruimin Zhao and Yiyan Cao and Yu Nan and Limei Fan and Zongyu Liu},
journal = {International journal of nanomedicine},
year = {2026},
month = nov,
doi = {10.2147/ijn.s649666},
url = {https://europepmc.org/article/MED/43011477},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Nanocarrier-Mediated Immunotherapy for Gynecological Malignancies: Mechanisms, Clinical Translation, and Emerging Nucleic Acid-Based Strategies.
AU - Miaomiao Fu
AU - Ruimin Zhao
AU - Yiyan Cao
AU - Yu Nan
AU - Limei Fan
AU - Zongyu Liu
PY - 2026
DA - 2026/11/06
JO - International journal of nanomedicine
DO - 10.2147/ijn.s649666
UR - https://europepmc.org/article/MED/43011477
AB - Gynecological cancers, including ovarian, cervical, and endometrial cancers, remain major contributors to female morbidity and mortality worldwide. Conventional treatments-surgery, chemotherapy, and radiotherapy-have improved outcomes, but advanced or recurrent disease is still associated with poor prognosis, chemoresistance, and tumor heterogeneity. Immunotherapy has emerged as a transformative strategy because of its specificity and potential for durable responses. However, the immunosuppressive tumor microenvironment and inefficient delivery of immunotherapeutic agents limit clinical benefit. Nanocarriers, including organic, inorganic, and biomimetic platforms, can improve targeted delivery, sustained release, biocompatibility, and tumor microenvironment remodeling, thereby enhancing immunotherapy. This review summarizes major immunotherapeutic modalities for gynecological cancers-immune checkpoint blockade, CAR-T cell therapy, tumor vaccines, and oncolytic viruses-and the classification and characteristics of commonly used nanocarriers. We focus on nanocarrier-mediated immunotherapeutic mechanisms in ovarian, cervical, and endometrial cancers, and further highlight emerging lipid nanoparticle/mRNA and programmable RNA delivery strategies. Finally, we analyze challenges in clinical translation and provide perspectives for future development, aiming to support fundamental research and clinical application of nano-immunotherapy in gynecological malignancies.
SN - 1176-9114
SN - 1178-2013
ER -